Stock Research for CNAT

CNAT

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

CNAT Stock Chart & Research Data

The CNAT chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CNAT chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


CNAT Due diligence Resources & Stock Charts

The CNAT stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View CNAT Detailed Price Forecast - CNN Money CNN View CNAT Detailed Summary - Google Finance
Yahoo View CNAT Detailed Summary - Yahoo! Finance Zacks View CNAT Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View CNAT Trends & Analysis - Trade-Ideas Barrons View CNAT Major Holders - Barrons
NASDAQ View CNAT Call Transcripts - NASDAQ Seeking View CNAT Breaking News & Analysis - Seeking Alpha
Spotlight View CNAT Annual Report - CompanySpotlight.com OTC Report View CNAT OTC Short Report - OTCShortReport.com
TradeKing View CNAT Fundamentals - TradeKing Charts View CNAT SEC Filings - Bar Chart
WSJ View Historical Prices for CNAT - The WSJ Morningstar View Performance/Total Return for CNAT - Morningstar
MarketWatch View the Analyst Estimates for CNAT - MarketWatch CNBC View the Earnings History for CNAT - CNBC
StockMarketWatch View the CNAT Earnings - StockMarketWatch MacroAxis View CNAT Buy or Sell Recommendations - MacroAxis
Bullish View the CNAT Bullish Patterns - American Bulls Short Pains View CNAT Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View CNAT Stock Mentions - StockTwits PennyStocks View CNAT Stock Mentions - PennyStockTweets
Twitter View CNAT Stock Mentions - Twitter Invest Hub View CNAT Investment Forum News - Investor Hub
Yahoo View CNAT Stock Mentions - Yahoo! Message Board Seeking Alpha View CNAT Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for CNAT - SECform4.com Insider Cow View Insider Transactions for CNAT - Insider Cow
CNBC View CNAT Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for CNAT - OTC Markets
Yahoo View Insider Transactions for CNAT - Yahoo! Finance NASDAQ View Institutional Holdings for CNAT - NASDAQ


Stock Charts

FinViz View CNAT Stock Insight & Charts - FinViz.com StockCharts View CNAT Investment Charts - StockCharts.com
BarChart View CNAT Stock Overview & Charts - BarChart Trading View View CNAT User Generated Charts - Trading View


Latest Financial News for CNAT

Conatus Pharmaceuticals’ Pan-caspase Inhibitor Emricasan Improves Survival and Portal Hypertension in a Mouse Model of Cirrhosis
Posted on Monday July 02, 2018

Conatus Pharmaceuticals Inc. (CNAT) today announced the publication1 of results from preclinical studies of its pan-caspase inhibitor emricasan, demonstrating improvements in portal hypertension (elevated blood pressure in the vein flowing into the liver) and survival in two bile duct ligation mouse models of induced secondary biliary cirrhosis. In the first of the two current mouse studies, designed to evaluate treatment effect, emricasan decreased fibrosis, reduced portal hypertension and improved survival in mice with cirrhosis induced by bile duct ligation. The reductions in portal hypertension exceeded amounts that could be explained by the decreased fibrosis alone, indicating potential treatment effects both inside and outside the liver.


NASH Space in Focus as Galmed (GLMD) Posts Positive Data
Posted on Thursday June 14, 2018

Investor focus is back on the NASH space as quite a few companies release promising data on their NASH candidates of late.


Why Is Conatus Pharmaceuticals (CNAT) Up 4.1% Since Its Last Earnings Report?
Posted on Friday June 01, 2018

Conatus Pharmaceuticals (CNAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.


Conatus' (CNAT) Q1 Loss In Line, Revenues Beat Estimates
Posted on Thursday May 03, 2018

Conatus (CNAT) reports in-line loss in Q1 while revenues beat estimates. Moreover, the top line improves year over year.


Enter a stock symbol to view the stock details.